This review examines the evidence for use of onabotulinumtoxinA in the treatment of neurogenic lower urinary tract dysfunction. Since its first use in 1988 to treat detrusor sphincter dyssynergia, use of botulinum toxin has increased in this group of patients. We discuss the mechanism of action, patient selection, dosing, efficacy, and side effect profile of this now licensed treatment option.
Keywords: botulinum toxin; detrusor sphincter dyssynergia; neurogenic bladder; neurogenic detrusor overactivity; onabotulinumtoxinA.